There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

WEIGHT-LOSS drugs can be a silver bullet for some trying to shed the pounds after years of failure with fad diets and exercise routines. But dodgy vendors selling potentially deadly fake jabs ...

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over ...